SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

SIBN 10.10.2024

Full Press ReleaseSEC FilingsOur SIBN Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024
  • 12.04.2024 - Piper Sandler Healthcare Conference
  • 11.20.2024 - SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities
PDF Version

SANTA CLARA, Calif.,Oct. 10, 2024(GLOBE NEWSWIRE) --SI-BONE, Inc.(Nasdaq: SIBN), aSilicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNTTM Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advancement over traditional cannulated screws.

TNT, which received 510(k) clearance inAugust 2024and was awarded Breakthrough Device Designation by the FDA, is the first 3D-printed transiliac-transsacral screw cleared for market use in theU.S.It features a pelvis-specific design to improve initial fixation and reduce the risk of screw backout. Among the first surgeons to perform procedures with TNT wereEdward Westrick, MD, atAllegheny General HospitalinPittsburgh, PA,Reza Firoozabadi, MD, atHarborview Medical CenterinSeattle, WA, J.D. Black, MD, atKadlec Regional Medical CenterinRichland, WA, andBrian Cunningham, MD, atMethodist Hospital–HealthPartnersinSt. Louis Park, MN.

“TNT went beyond my expectations,” saidDr. Black. “The streamlined instrumentation and implant design not only provided excellent fixation but also allowed for quick, precise implantation. This efficiency is critical when treating patients with fragile bones, as it reduces operating time, minimizes risks, and leads to faster recovery.”

“TNT’s 3D-printed porous surface facilitates osseointegration, which I believe will lead to better long-term outcomes for my older, osteoporotic patients,” saidDr. Cunningham, Vice Chair and Director of Orthopedics atMethodist Hospital–HealthPartners.

“We are thrilled with the successful completion of these initial procedures using our iFuse TORQ TNT system,” saidLaura Francis, Chief Executive Officer ofSI-BONE. “This breakthrough technology marks a significant step forward in addressing the unmet clinical needs of complex pelvic fragility fractures. By providing a solution that improves both surgical efficiency and patient recovery, we are further expanding our leadership in the sacropelvic space.”

AboutSI-BONE, Inc.

SI-BONE(NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009,SI-BONEhas supported over 3,900 surgeons in performing more than 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 135 peer-reviewed publications.SI-BONEhas leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.

For additional information on the company or its products, including risks and benefits, please visitwww.si-bone.com.

iFuse TORQ, iFuse Bedrock Granite, andSI-BONEare registered trademarks; iFuse TORQ TNT is a trademark ofSI-BONE, Inc.©2024SI-BONE, Inc.All Rights Reserved.Edward Westrick, MD,Reza Firoozabadi, MD, and J.D. Black, MD, are paid consultants forSI-BONE, Inc.Brian Cunningham, MD, is not a paid consultant forSI-BONE, Inc.

Investor Contact: Saqib Iqbalinvestors@si-bone.com

Primary Logo

Source: SI-BONE, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com